Nothing Special   »   [go: up one dir, main page]

RU94042903A - 3,4,4-трехзамещенные пиперидинил-n-алкилкарбоксилаты и промежуточные соединения, способ их получения, фармкомпозиция - Google Patents

3,4,4-трехзамещенные пиперидинил-n-алкилкарбоксилаты и промежуточные соединения, способ их получения, фармкомпозиция

Info

Publication number
RU94042903A
RU94042903A RU94042903/04A RU94042903A RU94042903A RU 94042903 A RU94042903 A RU 94042903A RU 94042903/04 A RU94042903/04 A RU 94042903/04A RU 94042903 A RU94042903 A RU 94042903A RU 94042903 A RU94042903 A RU 94042903A
Authority
RU
Russia
Prior art keywords
pharmcomposition
intermediate compounds
alkylcoarboxylates
preparation
trisubstituted
Prior art date
Application number
RU94042903/04A
Other languages
English (en)
Other versions
RU2145958C1 (ru
Inventor
Алан Фрэнк Скотт
Us]
Эдвард Претер Дуглас
Алан Уорд Джеффри
Арнольд Вернер Джон
Original Assignee
Эли Лилли энд Компани (US)
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли энд Компани (US), Эли Лилли Энд Компани filed Critical Эли Лилли энд Компани (US)
Publication of RU94042903A publication Critical patent/RU94042903A/ru
Application granted granted Critical
Publication of RU2145958C1 publication Critical patent/RU2145958C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретение относится к способу получения определенных 3,4,4-трехзамещенных пиперидинил- N-алкилкарбоксилатов, промежуточных соединений и родственных им соединений. В конечном счете, изобретение представляет новые 3,4,4-трехзамещенные пиперидинил -N-алкилкарбоксилаты вместе с композициями и методами для использования этих соединений.

Claims (1)

  1. Изобретение относится к способу получения определенных 3,4,4-трехзамещенных пиперидинил- N-алкилкарбоксилатов, промежуточных соединений и родственных им соединений. В конечном счете, изобретение представляет новые 3,4,4-трехзамещенные пиперидинил -N-алкилкарбоксилаты вместе с композициями и методами для использования этих соединений.
RU94042903A 1993-12-08 1994-12-02 3,4,4-трехзамещенные пиперидинил-n-алкилкарбоксилаты и промежуточные соединения, способ их получения и фармацевтическая композиция RU2145958C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/164.074 1993-12-08
US08/164,074 1993-12-08
US08/164,074 US5434171A (en) 1993-12-08 1993-12-08 Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates

Publications (2)

Publication Number Publication Date
RU94042903A true RU94042903A (ru) 1996-10-27
RU2145958C1 RU2145958C1 (ru) 2000-02-27

Family

ID=22592858

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94042903A RU2145958C1 (ru) 1993-12-08 1994-12-02 3,4,4-трехзамещенные пиперидинил-n-алкилкарбоксилаты и промежуточные соединения, способ их получения и фармацевтическая композиция

Country Status (31)

Country Link
US (1) US5434171A (ru)
EP (3) EP0657428B1 (ru)
JP (2) JP3834075B2 (ru)
KR (1) KR100356239B1 (ru)
CN (2) CN1057294C (ru)
AT (1) ATE200279T1 (ru)
AU (1) AU681198B2 (ru)
BR (1) BR9404842A (ru)
CA (1) CA2137221C (ru)
CO (1) CO4290427A1 (ru)
CZ (1) CZ290559B6 (ru)
DE (1) DE69427017T2 (ru)
DK (1) DK0657428T3 (ru)
ES (1) ES2155844T3 (ru)
FI (2) FI106455B (ru)
GR (1) GR3036136T3 (ru)
HK (1) HK1013826A1 (ru)
HU (1) HUT71489A (ru)
IL (1) IL111843A (ru)
MY (1) MY121543A (ru)
NO (1) NO302884B1 (ru)
NZ (1) NZ270039A (ru)
PE (1) PE41495A1 (ru)
PL (1) PL181734B1 (ru)
PT (1) PT657428E (ru)
RU (1) RU2145958C1 (ru)
SI (1) SI0657428T1 (ru)
TW (1) TW290540B (ru)
UA (1) UA52577C2 (ru)
YU (2) YU82304A (ru)
ZA (1) ZA949584B (ru)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722497B1 (fr) * 1994-07-13 1996-08-14 Synthelabo Esters de alpha-4-chlorophenyl)-4-(4-fluorophenyl)methyl) piperidine-1-ethanol, leur preparation et leur application en therapeutique
HN1999000149A (es) 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
ATE446751T1 (de) * 2001-06-05 2009-11-15 Univ Chicago Verwendung von methylnaltrexon zur behandlung von immunsuppression
US20030068829A1 (en) * 2001-06-25 2003-04-10 Symyx Technologies, Inc. High throughput crystallographic screening of materials
KR101009309B1 (ko) 2001-10-18 2011-01-18 넥타르 테라퓨틱스 아편양 길항제의 중합체 공액
US6794510B2 (en) * 2002-08-08 2004-09-21 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
US20040266806A1 (en) 2003-04-08 2004-12-30 Sanghvi Suketu P. Pharmaceutical formulation
US20050004155A1 (en) * 2003-04-08 2005-01-06 Boyd Thomas A. Use of methylnaltrexone to treat irritable bowel syndrome
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
FR2861304B1 (fr) * 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
US20050148630A1 (en) * 2003-12-02 2005-07-07 Carpenter Randall L. Methods of preventing and treating non-opioid induced gastrointestinal dysfunction
US8946262B2 (en) * 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
NZ548529A (en) 2003-12-16 2010-08-27 Nektar Therapeutics Pegylated small molecules
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
US7087749B2 (en) * 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
US20050240177A1 (en) * 2004-04-26 2005-10-27 Packaging Service Corporation Of Kentucky Electrosurgical forceps
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
WO2006020930A2 (en) * 2004-08-12 2006-02-23 Sapphire Therapeutics, Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US20060211733A1 (en) * 2005-03-04 2006-09-21 Adolor Corporation Methods of preventing and treating opioid bowel dysfunction
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006096626A2 (en) * 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AU2006265639A1 (en) * 2005-07-01 2007-01-11 Jenrin Discovery MAO-B inhibitors useful for treating obesity
US7914776B2 (en) * 2005-10-07 2011-03-29 Adolor Corporation Solid dispersions of opioid antagonists
US20070092576A1 (en) * 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
US7538110B2 (en) * 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
CN100383121C (zh) * 2006-03-07 2008-04-23 天津泰普药品科技发展有限公司 阿韦苄酯化合物及其制备方法和以该化合物制备阿韦莫哌的工艺
ATE516021T1 (de) 2006-04-21 2011-07-15 Dsm Ip Assets Bv Verwendung von opioid-rezeptor-antagonisten
JP2010510329A (ja) * 2006-11-22 2010-04-02 プロジェニックス ファーマスーティカルス インコーポレーテッド ７，８−飽和−４，５−エポキシ−モルフィナニウム類似体
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
CA2865389A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
MX2011001583A (es) 2008-08-11 2011-04-04 Nektar Therapeutics Conjugados de alcanoato polimericos de multiples brazos.
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN101429154B (zh) * 2008-11-14 2011-01-05 天津泰普药品科技发展有限公司 无水阿维莫泮及其药物组合物
US20100311782A1 (en) 2009-06-08 2010-12-09 Adolor Corporation Substituted piperidinylpropanoic acid compounds and methods of their use
RS58894B1 (sr) 2009-12-04 2019-08-30 Alkermes Pharma Ireland Ltd Derivati morfinana za lečenje predoziranja lekom
WO2011161646A2 (en) 2010-06-25 2011-12-29 Ranbaxy Laboratories Limited Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
CN103360302B (zh) * 2012-03-29 2015-08-26 北大方正集团有限公司 阿维莫泮的纯化方法
GB2545368B (en) 2014-10-20 2021-04-21 Elysium Therapeutics Inc Diversion-resistant opioid formulations
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
GB2556817B (en) 2015-10-01 2019-11-06 Elysium Therapeutics Inc Polysubunit opioid prodrugs resistant to overdose and abuse
JP7234130B2 (ja) 2017-03-17 2023-03-07 エリージウム セラピューティクス， インコーポレイテッド 過剰摂取および乱用に対して抵抗性のポリサブユニットオピオイドプロドラッグ

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136040A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Preparation of substituted tetrahydropyridines
NZ242117A (en) * 1991-03-29 1994-11-25 Lilly Co Eli 4-phenylpiperidine derivatives and medicaments containing them
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists

Also Published As

Publication number Publication date
MY121543A (en) 2006-02-28
AU7917094A (en) 1995-06-15
EP0657428A1 (en) 1995-06-14
IL111843A0 (en) 1995-03-15
CZ290559B6 (cs) 2002-08-14
JP2006070042A (ja) 2006-03-16
HK1013826A1 (en) 1999-09-10
NO944644D0 (no) 1994-12-02
YU49312B (sh) 2005-06-10
FI106860B (fi) 2001-04-30
CN1111239A (zh) 1995-11-08
JP3834075B2 (ja) 2006-10-18
TW290540B (ru) 1996-11-11
EP0984004A3 (en) 2003-10-15
ATE200279T1 (de) 2001-04-15
CZ299294A3 (en) 1995-10-18
ES2155844T3 (es) 2001-06-01
PL181734B1 (pl) 2001-09-28
CA2137221C (en) 2011-02-22
NZ270039A (en) 1996-08-27
FI945703A0 (fi) 1994-12-02
ZA949584B (en) 1996-06-03
HUT71489A (en) 1995-11-28
RU2145958C1 (ru) 2000-02-27
DE69427017D1 (de) 2001-05-10
CN1121387C (zh) 2003-09-17
DE69427017T2 (de) 2001-09-06
FI20000353A (fi) 2000-02-17
PL306068A1 (en) 1995-06-12
CN1223257A (zh) 1999-07-21
BR9404842A (pt) 1995-08-08
EP1607387A2 (en) 2005-12-21
KR100356239B1 (ko) 2002-12-26
EP0657428B1 (en) 2001-04-04
UA52577C2 (ru) 2003-01-15
YU82304A (sh) 2006-03-03
YU70294A (sh) 1997-07-31
AU681198B2 (en) 1997-08-21
NO944644L (no) 1995-06-09
KR950017957A (ko) 1995-07-22
SI0657428T1 (en) 2001-08-31
GR3036136T3 (en) 2001-09-28
FI106455B (fi) 2001-02-15
US5434171A (en) 1995-07-18
HU9403466D0 (en) 1995-02-28
FI945703A (fi) 1995-06-09
EP1607387A3 (en) 2007-01-03
EP0984004A2 (en) 2000-03-08
NO302884B1 (no) 1998-05-04
JPH07215937A (ja) 1995-08-15
CN1057294C (zh) 2000-10-11
PE41495A1 (es) 1995-11-28
PT657428E (pt) 2001-07-31
CO4290427A1 (es) 1996-04-17
CA2137221A1 (en) 1995-06-09
IL111843A (en) 2000-02-29
DK0657428T3 (da) 2001-05-07

Similar Documents

Publication Publication Date Title
RU94042903A (ru) 3,4,4-трехзамещенные пиперидинил-n-алкилкарбоксилаты и промежуточные соединения, способ их получения, фармкомпозиция
NO160364C (no) Nytt mellomprodukt og fremgangsmaate ved fremstilling derav
DK1082293T3 (da) Formoterol-polymorfer
NO178764C (no) Fremgangsmåte ved fremstilling av oksetanoner
RU94044348A (ru) Производные 1-арилпиразола, способ и промежуточные продукты для их получения, средство борьбы с вредителями и способ получения средства для борьбы с вредителями
EA200201245A1 (ru) Способы получения и промежуточные соединения для получения противораковых соединений
RU94027577A (ru) Производные 1-бензолсульфонил-1,3-дигидро-2н-бензимидазол-2-она, способ их получения, содержащая их фармацевтическая композиция
RU94027573A (ru) Замещенные пиразолилпиразолы и способ их получения
EA200200940A1 (ru) Производные азетидина, способ их получения и содержащие их фармацевтические композиции
NO955047L (no) Sekundære aminer som antidiabetiske og antifedme-midler
DE69122866D1 (de) Herstellung von substituierten piperidinen
RU94022277A (ru) Новые 19-норстероиды, имеющие в положении 11 - бета феноксиалкилсульфонамидную или феноксиалкилсульфонилкарбамидную цепь, метод и промежуточные продукты их получения, и содержащая их фармацевтическая композиция
RU94036749A (ru) Замещенные 1-нафтилпиразол-3-карбоксамиды, способ их получения, содержащие их фармацевтические композиции и промежуточные соединения синтеза
ATE236139T1 (de) Verfahren zur herstellung von 2-chlor-5- chlomethyl-thiazol-derivaten
PT92180A (pt) Processo para a preparacao de novas mevalonolactonas do tipo tienopiridina e de composicoes farmaceuticas que as contem
DE60235365D1 (de) Verfahren zur herstellung von 7-amino-syn-3,5-dihydroxyheptansäurederivaten und zwischenverbindungen diesesverfahrens und deren herestellung
BR9408223A (pt) Composto derivado de 4-benzoilisoxazol processo de preparação composição herbicida método de controle herbicida e compostos intermediarios
EA199800354A1 (ru) Способ получения производных камптотецина
MY107160A (en) N-aryl-3-aryl-4-substituted-4,5-dihydro-1h-pyrazole-1- carboxamides and processes for their production.
RU95112519A (ru) (3,4-ди-фторфенокси)метил оксиран и способ его получения
RU95107655A (ru) Глюкопиранозидбензотиофены, способ получения, фармацевтическая композиция
AU1193597A (en) Process for the preparation of 2-chloro-5-chloromethyl-thiazole
ZA200005110B (en) Process for preparing intermediates.
RU94037761A (ru) Способ получения 3-ацилэстратриенов и ацилбензолов
EA200301133A1 (ru) Способ получения дифторбензилэпоксидов и промежуточные соединения

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20101203